Drilldown: Medicines

Glimepiride (1) · Terbinafine (1)

Amaryl (1) · Lamisil; OTC topical Lamisil AT (1)

[[:Category:Allylamines|Allylamine]] (1) · [[:Category:Antifungals|Antifungal (allylamine)]] (1) · [[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (1) · [[:Category:Insulin_secretagogues|Insulin secretagogue]] (1) · [[:Category:Sulfonylureas|Sulfonylurea (third-generation)]] (1)

None (2)

'"`UNIQ--vote-00000491-QINU`"' (1) · '"`UNIQ--vote-00000EAF-QINU`"', '"`UNIQ--vote-00000EB0-QINU`"', '"`UNIQ--vote-00000EB1-QINU`"' (1)

1-2 mg PO once daily with breakfast; titrate by glycemic response (1) · Oral: 250 mg PO once daily × 6 weeks (fingernails) or 12 weeks (toenails); topical: cream BID × 1-2 weeks (1)

1 mg, 2 mg, 4 mg tablets (1) · 250 mg tablets; 1% topical cream, gel, spray; granules (pediatric) (1)

250 mg/d (1) · 8 mg/d (1)

Oral (2) · topical (1)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

None · 24 hours · 4-6 hours · 12 hours · 6-8 hours · Daily dosing · 8-12 hours · 12-24 hours · Hours · Hours per application · 24 hours (HS dosing) · 24 hours (once-daily dosing) · 24 h · N/A · N/A (replacement) · Variable · ~7-8 hours · 3-5 hours · 4-6 hours (IR); 24 hours (ER) · 6-12 hours

Other values:

Search

~36 hours (terminal much longer due to tissue accumulation in skin/nails)'"`UNIQ--ref-00000EB2-QINU`"' (1) · ~5-9 hours (parent and active metabolites combined)'"`UNIQ--ref-00000492-QINU`"' (1)

~100% (oral; not significantly affected by food)'"`UNIQ--ref-00000493-QINU`"' (1) · ~40% (oral; food does not significantly affect)'"`UNIQ--ref-00000EB3-QINU`"' (1)

Avoid; switch to insulin. Neonatal hypoglycemia reported.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited data; generally avoided in pregnancy for the cosmetic indication of onychomycosis.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

OTC (topical) and [[USLegal:Prescription only|Rx-only]] (oral) in US (1) · [[USLegal:Prescription only|Rx-only]] in US (1)